NeurAxis is a fast-growing medtech company
Developing and commercializing neuromodulation therapies to address chronic and debilitating conditions, NeurAxis focuses on targeted therapies for patients suffering from disorders of the gut-brain interaction (DGBI), including functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia (FD), and FD-related nausea symptoms.
NeurAxis is dedicated to advancing the science with its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on our unparalleled body of clinical evidence is necessary for adoption by the medical and scientific community.
Additional clinical trials of PENFS in multiple pediatric conditions are underway, focusing on unmet healthcare needs for chronic abdominal pain and other DGBI-related conditions.
Established as a privately held company in 2012, NeurAxis went public in August 2023 (NYSEAMERICAN: NRXS).
Reimagine
Research
Innovate
Through innovation and research, we are reimagining the future of patient care so all patients can experience the lifelong benefits of being free from chronic abdominal pain, and other DGBI conditions.
The NeurAxis Mission
Improve lives by creating safe and effective treatments that mitigate debilitating pain and alleviate suffering. We aim to establish a new standard of care for patients with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms.
Neuromodulation Therapies for Chronic and Debilitating Conditions
Neuromodulation Therapies for Chronic and Debilitating Conditions
Targeted therapies for patients suffering from disorders of the gut-brain interaction (DGBI): functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia (FD), and FD-related nausea symptoms.
